Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)

Breast

Volumn 10, Issue SUPPL. 2, 2001, Pages 1-7

  Swenson, C E ^a   Perkins, W R ^a   Roberts, P ^a   Janoff, A S ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; DOXORUBICIN; DRUG CARRIER; LIPOSOME; SODIUM CHLORIDE;

ADULT; AGED; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOG; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DYSESTHESIA; ENCAPSULATION; FEMALE; FOOT DISEASE; GASTROINTESTINAL HEMORRHAGE; HAND DISEASE; HEART; HUMAN; MALE; MEMBRANE VESICLE; MOUSE; NONHUMAN; PH; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; TARGET ORGAN; TUMOR VASCULARIZATION;

EID: 0034988577     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2000.0201     Document Type: Review

References (26)

1. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: From metastatic to adjuvant setting
2. Combination therapy for advanced breast cancer: Cyclophosphamide, 'doxorubicin, UFT, and tamoxifen
3. Antineoplastic agents
4. The unique physiology of solid tumours: Opportunities (and problems) for cancer therapy
5. Preparation of Liposomes Entrapping Cancer Chemotherapeutic Agents for Experimental In Vivo and In Vitro Studies
6. Liposomes as Pharmaceuticals
7. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection
8. Liposome disposition in vivo: III. Dose and vesicle-size effects
9. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumours
10. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey
11. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
12. Complexation of internalized doxorubicin into fibre bundles affects its release rate from liposomes
13. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient
14. Gelation of liposome interior: A novel method for drug encapsulation
15. Comparison of free and liposome encapsulated doxorubicin tumour drug uptake and antitumour efficacy in the SC115 murine mammary tumour
16. Tissue distribution of doxorubicin in the free and liposomal forms in male beagles
17. Anthracyclines: A review of general and special toxicity studies
18. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs
19. Distribution of doxorubicin fluorescence in a human breast carcinoma (MCF7) grown on SCID mice after treatment with Evacet or free doxorubicin
20. Doxorubicin fluorescence in a human breast carcinoma (MX-1) after treatment with liposome-associated or free doxorubicin
21. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly(ethylene glycol)
22. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
23. Safety aspects of pegylated liposomal doxorubicin in patients with cancer
24. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy